Welcome to LookChem.com Sign In|Join Free

CAS

  • or

58994-96-0

Post Buying Request

58994-96-0 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

58994-96-0 Usage

Description

Ranimustine, also known by its brand name Cymerine, is a novel nitrosourea derivative that serves as a water-soluble antitumor agent. It is characterized by its low hematological toxicity and diabetogenic effect, making it a promising candidate for cancer treatment. Ranimustine is particularly effective in the treatment of hematologic malignancies, specifically myeloproliferative disorders.

Uses

Used in Oncology:
Ranimustine is used as an antitumor agent for the treatment of hematologic malignancies, particularly myeloproliferative disorders. It exhibits low hematological toxicity and a reduced diabetogenic effect, which contribute to its effectiveness in this application.
Used in Anti-Inflammatory Applications:
Ranimustine is also utilized as a glucocorticoid with low systemic absorption, making it an effective anti-inflammatory agent. This application takes advantage of its ability to provide targeted relief with minimal systemic side effects.

Originator

Tokyo Tanabe (Japan)

Check Digit Verification of cas no

The CAS Registry Mumber 58994-96-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,8,9,9 and 4 respectively; the second part has 2 digits, 9 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 58994-96:
(7*5)+(6*8)+(5*9)+(4*9)+(3*4)+(2*9)+(1*6)=200
200 % 10 = 0
So 58994-96-0 is a valid CAS Registry Number.
InChI:InChI=1/C10H18ClN3O7/c1-20-9-8(17)7(16)6(15)5(21-9)4-12-10(18)14(13-19)3-2-11/h5-9,15-17H,2-4H2,1H3,(H,12,18)

58994-96-0SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 13, 2017

Revision Date: Aug 13, 2017

1.Identification

1.1 GHS Product identifier

Product name Ranimustine

1.2 Other means of identification

Product number -
Other names 1-(2-chloroethyl)-1-nitroso-3-[[(2r,3s,4s,5r,6s)-3,4,5-trihydroxy-6-methoxy-oxan-2-yl]methyl]urea

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:58994-96-0 SDS

58994-96-0Downstream Products

58994-96-0Relevant articles and documents

In the search for new anticancer drugs. XXIII: Exploration of a predictive design for anticancer drugs of carbohydrates containing N-nitrosochloroethylamino, N-nitrosomethyl, and N-nitrosoaminoxyl components

Sosnovsky,Rao

, p. 693 - 699 (2007/10/02)

The spin-labeled glucose nitrosoureas 13-16, streptozotocin (18), chlorozotocin (31), streptozotocin analogues of galactosyl 24 and mannosyl 28, and their tetra-O-acetyl derivatives 25 and 29, MCNU (Cymerin, 34), and glucamine (21) were synthesized and evaluated in vivo for their anticancer activities against the murine lymphocytic leukemia P388. Compounds 13-16, 18, 24, 28, 31, and 34 possessed activities ranging from 33 to 603% increase in life span (%ILS), whereas 21, 25, and 29 were inactive (%ILS = 9 to 10). All CD2F1 male mice treated with the most active compounds (13, 14, and 34) at 20 mg/kg were alive after 30 days, whereas all mice treated with the clinical drug streptozotocin (18) and clinically tested chlorozotocin (31) succumbed. Compounds 13-16, 18, 31, and 34 were further evaluated for their antineoplastic activity against lymphoid leukemia L1210. Compounds 13 and 34 on day 60 exhibited %ILS values of 557 and 713, respectively, as compared with %ILS values of 646 and 713 for CCNU (1) and the spin-labeled SLCNU (3), respectively. The lipophilicities of 13-16, 18, 21, 24, 25, 28, 29, 31, and 34 were determined using EPR and/or UV methods. A predictive design pattern was observed, with the most active drug (34) possessing some hydrophobic property (log P = 1.24), followed by 13 (log P = 1.87) and 14 (log P = 1.81) as the more active drugs with higher hydrophobicity than 34. The clinical drugs streptozotocin (18) and chlorozotocin (31) were distinctly hydrophilic and less active. Finally, it was concluded that various scattered results of anticancer activity in the literature can be explained by a linear correlation of activities with lipophilicities.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 58994-96-0